Microbiota-liver axis in hepatic disease.

Microbiota-liver axis in hepatic disease.
复制标题

肝脏疾病中的微生物群-肝轴。

DOI:
10.1002/hep.26494
复制
发表时间:
2014-01
期刊:
影响因子:
13.5
通讯作者:
Gewirtz, Andrew T.
Gewirtz, Andrew T.
中科院分区:
医学1区
文献类型:
--
作者:
Chassaing, Benoit;Etienne-Mesmin, Lucie;Gewirtz, Andrew T.

文献摘要

参考文献

被引文献

相似文献

越来越多的证据表明,肠道微生物区系长期以来被认为是肠道炎症的关键决定因素,也在肝脏慢性炎症性疾病中发挥着关键作用。这些研究已经产生了一个普遍的中心假说,即微生物区系产品激活先天免疫系统以驱动促炎基因的表达,从而促进肝脏的慢性炎症性疾病。本文综述了支持这一假说的背景,概述了它如何潜在地解释经典的和新出现的流行病学慢性炎症性肝病,并讨论了操纵微生物区系以预防和/或治疗肝病的潜在治疗手段。
Accumulating evidence indicates that the gut microbiota, long appreciated to be a key determinant of intestinal inflammation, is also playing a key role in chronic inflammatory disease of the liver. Such studies have yielded a general central hypothesis whereby microbiota products activate the innate immune system to drive pro-inflammatory gene expression thus promoting chronic inflammatory disease of the liver. This article reviews the background supporting this hypothesis, outlines how it can potentially explain classic and newly emerging epidemiological chronic inflammatory liver disease, and discusses potential therapeutic means to manipulate the microbiota so as to prevent and/or treat liver disease.
DOI: 10.2337/db06-1491
发表时间: 2007-07-01
期刊: DIABETES
影响因子: 7.7
作者:
Cani, Patrice D.;Amar, Jacques;Burcelin, Remy
通讯作者: Burcelin, Remy
DOI: 10.1152/ajpgi.00163.2009
发表时间: 2011-03-01
影响因子: 4.5
作者:
Csak, Timea;Velayudham, Arumugam;Szabo, Gyongyi
通讯作者: Szabo, Gyongyi
DOI: 10.1152/ajpgi.2001.280.6.g1280
发表时间: 2001-06-01
影响因子: 4.5
作者:
Atkinson, KJ;Rao, RK
通讯作者: Rao, RK
DOI: 10.1016/j.ccr.2012.02.007
发表时间: 2012-04-17
期刊: Cancer cell
影响因子: 50.3
作者:
Dapito DH;Mencin A;Gwak GY;Pradere JP;Jang MK;Mederacke I;Caviglia JM;Khiabanian H;Adeyemi A;Bataller R;Lefkowitch JH;Bower M;Friedman R;Sartor RB;Rabadan R;Schwabe RF
通讯作者: Schwabe RF
DOI: 10.1371/journal.pone.0023037
发表时间: 2011
期刊: PloS one
影响因子: 3.7
作者:
Gómez-Hurtado I;Santacruz A;Peiró G;Zapater P;Gutiérrez A;Pérez-Mateo M;Sanz Y;Francés R
通讯作者: Francés R